A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002151
- Lead Sponsor
- Hoechst Marion Roussel
- Brief Summary
To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection. To examine the demographic effects on population pharmacokinetics and pharmacodynamics of MDL 28,574A alone and in combination with AZT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (23)
Clinical Investigations Health Services
🇺🇸Mobile, Alabama, United States
California Clinical Trials Med Group
🇺🇸Beverly Hills, California, United States
Southwest Community Based AIDS Treatment Group - COMBAT
🇺🇸Los Angeles, California, United States
UCSF - San Francisco Gen Hosp
🇺🇸San Francisco, California, United States
George Washington Univ / Hershey Med Ctr
🇺🇸Washington, District of Columbia, United States
Community Research Initiative of South Florida
🇺🇸Coral Gables, Florida, United States
Independent Investigator
🇺🇸Vero Beach, Florida, United States
North Broward Hosp District
🇺🇸Fort Lauderdale, Florida, United States
Clinical Research Ctr
🇺🇸Sarasota, Florida, United States
Ctr for Special Immunology
🇺🇸Chicago, Illinois, United States
Scroll for more (13 remaining)Clinical Investigations Health Services🇺🇸Mobile, Alabama, United States